ACAD

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Kihara JamesPRINCIPAL ACCOUNTING OFFICER --5.4k shares SellMay 26, 2026 $114.4K5.4k shares $21.18 $21.63

News

zacks.comAcadia (ACAD) Down 3.7% Since Last Earnings Report: Can It Rebound?zacks.comJun 5

marketbeat.comACADIA Pharmaceuticals Spotlights Alzheimer's Psychosis Pipeline, NUPLAZID and DAYBUE Growthmarketbeat.comMay 19

seekingalpha.comACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.comMay 12

marketbeat.comACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Loomsmarketbeat.comMay 12

zacks.comACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growthzacks.comMay 7

Trade ACAD

About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.

CEO: Catherine E. Owen Adams
IPO Date: May 27, 2004

Market Data

Open: $21.71
High: $21.96
Low: $21.45
Volume: 771.4K
52W High: $28.35
52W Low: $19.69

Valuation

Market Cap: $3.7B
Enterprise Value: $3.5B

Financials

Free Cash Flow: $105M
Revenue: $1.1B
Net Income: $391M
Cash: $178M
Debt: $52M

Events

EarningsAug 5

EPS est. 0.06